March 19, 2018 / 12:11 PM / a month ago

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

March 19 (Reuters) - Heron Therapeutics Inc:

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

* HERON THERAPEUTICS INC - HTX-011 ACHIEVED ALL PRIMARY AND KEY SECONDARY ENDPOINTS

* HERON THERAPEUTICS INC - SIGNIFICANTLY MORE PATIENTS RECEIVING HTX-011 WERE OPIOID-FREE THROUGH 72 HOURS AFTER SURGERY

* HERON THERAPEUTICS INC - SIGNIFICANTLY FEWER HTX-011 PATIENTS EXPERIENCED SEVERE PAIN AT ANY TIME

* HERON THERAPEUTICS INC - NDA FILING FOR HTX-011 TARGETED FOR H2 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below